Drug Tolerance
Research News and Information

Sunday, November 22, 2009

Effect of anti-IFN{beta} antibodies on MRI lesions of MS patients in the BECOME study.

Nov 2009 BACKGROUND: Interferon beta (IFNbeta) administered subcutaneously is immunogenic in some patients with multiple sclerosis (MS) and leads to the development of neutralizing antibodies (NAbs). Considerable evidence has accumulated that NAbs diminish ... Read more...

Effects of telmisartan, ramipril, and their combination on left ventricular hypertrophy in individuals at high vascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease.

19 Sep 2009 BACKGROUND: Angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers reduce left ventricular hypertrophy (LVH). The effect of these drugs on LVH in high-risk patients without heart failure is unknown. METHODS AND RESULTS: In ... Read more...

[Anti-opioid action of glutamate-NMDA receptor systems underlying morphine analgesic tolerance]

30 Aug 2009 Although the opioid analgesics such as morphine represent an important class of agents for the treatment of severe clinical pain, the development of tolerance and dependence often overshadows the therapeutic advantages of morphine and related ... Read more...

Latest indexed articles for 'Drug Tolerance'

These are the very latest articles for this heading:

• Effect of anti-IFN{beta} antibodies on MRI lesions of MS patients in the BECOME study. Nov 2009
• Decreased clinical response to adalimumab in ankylosing spondylitis is associated with antibody formation. 30 Oct 2009
• Effects of telmisartan, ramipril, and their combination on left ventricular hypertrophy in individuals at high vascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease. 19 Sep 2009
• [Anti-opioid action of glutamate-NMDA receptor systems underlying morphine analgesic tolerance] 30 Aug 2009
• Linezolid: a review of safety and tolerability. 30 Aug 2009
• Revisiting tolerance from the endogenous morphine perspective. 30 Aug 2009
• What is the rate of loss of response to infliximab therapy in Crohn's disease? 30 Aug 2009
• Central administration of minocycline and riluzole prevents morphine-induced tolerance in rats. 30 Aug 2009
• Alpha2-receptor agonists for treatment and prevention of iatrogenic opioid abstinence syndrome in critically ill patients. 16 Aug 2009
• Solvent tolerance acquired by Brevibacillus brevis during an olive-waste vermicomposting process. 6 Aug 2009
• In response to van Spronsen et al (2009) phenylalanine tolerance can already reliably be assessed at the age of 2 years in patients with PKU (J Inherit Metab Dis 32: 27-31). 30 Jul 2009
• The hepatic safety and tolerability of the cyclooxygenase-2 selective NSAID celecoxib: pooled analysis of 41 randomized controlled trials. 30 Jul 2009
• Environmental and pharmacological factors in the development of noncontingent tolerance to cocaine in pigeons. 30 Jul 2009
• Safety profile and clinical outcomes in a phase I, placebo-controlled study of siplizumab in acute graft-versus-host disease. 25 Jul 2009
• Spinal ceramide and neuronal apoptosis in morphine antinociceptive tolerance. 21 Jul 2009
• Suppressive effects of lamotrigine on the development and expression of tolerance to morphine-induced antinociception in the male mouse. 13 Jul 2009
• Do opioids induce hyperalgesia in humans? An evidence-based structured review. 4 Jul 2009
• Anti-inflammatory, immunomodulatory and antinociceptive activity of Terminalia arjuna Roxb bark powder in mice and rats. 29 Jun 2009
• Prevention and reversal of morphine tolerance by the analgesic neuroactive steroid alphadolone. 29 Jun 2009
• Bendamustine therapy in chronic lymphocytic leukemia. 29 Jun 2009

See a longer list of these articles.

Technical information about 'Drug Tolerance'

Definition: Progressive diminution of the susceptibility of a human or animal to the effects of a drug, resulting from its continued administration. It should be differentiated from DRUG RESISTANCE wherein an organism, disease, or tissue fails to respond to the intended effectiveness of a chemical or drug. It should also be differentiated from MAXIMUM TOLERATED DOSE and NO-OBSERVED-ADVERSE-EFFECT LEVEL.

Descriptor UI: D004361

Alternative terms: Drug Tolerance; Drug Tolerances; Tolerance, Drug; Tolerances, Drug;

Allowable Qualifiers: ethnology; genetics; immunology; physiology; radiation effects;

Tree Number: G07.690.812.260; G07.700.680.260;

Technical Notes: differentiate from DRUG RESISTANCE; not for tolerability ( = drug /adv eff): Manual 28.19